Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMI-135 + MKC-3946 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMI-135 | BMI135|BMI 135 | BMI-135 is a selective human ER partial agonist (ShERPA), potentially resulting in increased apoptosis and decreased cell proliferation (PMID: 32788222). | ||
MKC-3946 | MKC 3946|MKC3946 | MKC-3946 is small molecule drug that targets the endoribonuclease domain of Ire1 alpha (ERN1) and inhibits XBP1 splicing, potentially resulting in increased apoptosis and decreased tumor growth (PMID: 22538852). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|